HUMORAL MARKERS, CONVENTIONAL DOPPLER ECHOCARDIOGRAM AND BIDIMENSIONAL STRAIN IN THE DETECTION OF MYOCARDIAL TOXIC EFFECT SECONDARY TO CHEMOTHERAPY  by Baratta, Sergio J. et al.
Non Invasive Imaging
A1177
JACC April 1, 2014
Volume 63, Issue 12
hUMoral Markers, convenTional doppler echocardiograM and BidiMensional sTrain in 
The deTecTion of Myocardial Toxic effecT secondary To cheMoTherapy
Poster Contributions
Hall C
Sunday, March 30, 2014, 3:45 p.m.-4:30 p.m.
Session Title: Non Invasive Imaging: Myocardial Strain, Cardiac Mechanics and Diastolic Function
Abstract Category: 15. Non Invasive Imaging: Echo
Presentation Number: 1210-32
Authors: Sergio J. Baratta, Alejandro Benticuaga Navas, Jose Trucco, Demian Chejtman, Maria Noelia Brenzoni, Mercedes Rojas, Renzo E. 
Melchiori, Jorge Bilbao, Horacio Fernandez, Alejandro Hita, Hospital Universitario Austral, Buenos Aires, Argentina
Background: Aim: Analyze the usefulness of humoral markers (quantitative troponin T (TT), BNP, NT pro-BNP), conventional and the two-
dimensional longitudinal strain (LS), and radial strain (RS) in the prediction of ventricular systolic dysfunction in patients treated with cardiotoxic 
chemotherapy.
Methods: Thirty six patients (average age (±SD) 47±16 years, 42% men) with neoplasic disease with normal left ventricular ejection fraction (LVEF) 
≥ 55% and no cardiovascular history scheduled to receive chemotherapy with potential cardiotoxicity were prospectively included. TT, BNP, NT pro-
BNP, conventional echocardiogram, LS, RS, CS (circunferencial strain) were performed before chemotherapy and at 2, 3, 4 and 6 months after the 
start of cancer treatment. Cardiotoxicity end point (EP) was defined as a reduction of the LVEF of ≥5% to <55% with symptoms of heart failure or an 
asymptomatic reduction of the LVEF of ≥10% to <55%.
results: Seven patients reached the EP ((19.4%, G1: positive EP), (G2 :negative EP, n:29)). Following a univariate analysis, predictors related to the 
EP were: NT pro-BNP at 4 months (G1: 152 ±42 pg/ml vs G2 61±38 pg/ml, p< 0.001), BNP at 4 months (G1 41±12 pg/ml vs G2 26±11 pg/ml , p< 
0.01), LS at 3 months (G1 - 16.3±2.4% vs G2 -19.6±2.02%, p< 0.01) and at 4 months (G1 - 15.9±1.77% vs G2 - 19.9±2.2%, p< 0.001), RS at 4 
months (G1 46.4±2.4% vs G2 52±3.4%, p< 0.001). For the detection of systolic dysfunction at 6 months, a cut-off point of NT pro-BNP at 4 months 
of 97 pg/ml had a sensitivity of 85% and a specificity of 86%. and a cut-off point of BNP at 4 months of 31 pg/ml had a sensitivity of 86% and a 
specificity of 79%. A reduction of the LS≥15% at 3 months had a sensitivity of 86% and a specificity of 86% for the detection of systolic dysfunction 
at 6 months and a reduction of the RS ≥10% at 4 months had a sensitivity of 86% and a specificity of 69%.
conclusions: The dosage of natriuretic peptides and the measurement of the radial and longitudinal two-dimensional strain after the start 
of cancer treatment could be useful to predict slight degree ventricular systolic dysfunction in patients treated with potentially cardiotoxic 
chemotherapy.
